Rochester neurologist to lead biggest clinical trial ever of Parkinson's disease

December 20, 2001

A neurologist at the University of Rochester Medical Center has been chosen to lead the largest study ever of patients with Parkinson's disease.

Professor of Neurology Karl Kieburtz, M.D., will lead the study of 3,000 patients around the country who have Parkinson's disease; the statistical component of the study will be headed by scientists at the Medical University of South Carolina. The five-year study, to be launched in late 2002 or in 2003, will be funded with approximately $6.5 million from the National Institute of Neurological Disorders and Stroke, a component of the National Institutes of Health.

The study is the largest effort yet to find a way to slow the progression of the disease. About one million adults in North America have Parkinson's disease, in which several hundred thousand cells in a tiny region of the brain known as the substantia nigra degenerate and die. This results in symptoms that include slowness of movement, difficulty walking and swallowing, muscle stiffness, tremors, and rigidity.

Currently doctors use a range of medications to treat the symptoms, but there is no way to slow or prevent the death of brain cells that is at the heart of the disease.

"There is not a lot out there at this point to protect patients from further damage," says Kieburtz. "We have several candidates, but thus far none has been shown to slow the disease."

Kieburtz will coordinate doctors from 42 sites around North America who will track the health of the patients over a five-year period. The team will test the effectiveness of various substances at slowing the progression of the disease. Possibilities include obscure compounds in development in laboratories, as well as everyday substances like caffeine and nicotine.

In similar studies bringing together doctors and patients around the country, Medical Center physicians recently led a team that found that a skin patch under development to treat Parkinson's disease appears as effective as traditional oral medications. Last year doctors led another international team that showed that doctors now have a choice of treatments for newly diagnosed patients. The research is being done through the Department of Neurology's Clinical Trials Coordination Center, where Kieburtz serves as director.
-end-


University of Rochester Medical Center

Related Disease Articles from Brightsurf:

CLCN6 identified as disease gene for a severe form of lysosomal neurodegenerative disease
A mutation in the CLCN6 gene is associated with a novel, particularly severe neurodegenerative disorder.

Cellular pathway of genetic heart disease similar to neurodegenerative disease
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure.

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered
The link between periodontal (gum) disease and other inflammatory conditions such as heart disease and diabetes has long been established, but the mechanism behind that association has, until now, remained a mystery.

Potential link for Alzheimer's disease and common brain disease that mimics its symptoms
A new study by investigators from Brigham and Women's Hospital uncovered a group of closely related genes that may capture molecular links between Alzheimer's disease and Limbic-predominant Age-related TDP-43 Encephalopathy, or LATE, a recently recognized common brain disorder that can mimic Alzheimer's symptoms.

Antioxidant agent may prevent chronic kidney disease and Parkinson's disease
Researchers from Osaka University developed a novel dietary silicon-based antioxidant agent with renoprotective and neuroprotective effects.

Tools used to study human disease reveal coral disease risk factors
In a study published in Scientific Reports, a team of international researchers led by University of Hawai'i (UH) at Mānoa postdoctoral fellow Jamie Caldwell used a statistical technique typically employed in human epidemiology to determine the ecological risk factors affecting the prevalence of two coral diseases--growth anomalies, abnormalities like coral tumors, and white syndromes, infectious diseases similar to flesh eating bacteria.

Disease-aggravating mutation found in a mouse model of neonatal mitochondrial disease
The new mitochondrial DNA (mtDNA) variant drastically speeds up the disease progression in a mouse model of GRACILE syndrome.

Human longevity largest study of its kind shows early detection of disease & disease risks
Human Longevity, Inc. (HLI) announced the publication of a ground-breaking study in the journal Proceedings of the National Academy of Sciences (PNAS).

30-year study identifies need of disease-modifying therapies for maple syrup urine disease
A new study analyzes 30 years of patient data and details the clinical course of 184 individuals with genetically diverse forms of Maple Syrup Urine Disease (MSUD), which is among the most volatile and dangerous inherited metabolic disorders.

Long-dormant disease becomes most dominant foliar disease in New York onion crops
Until recently, Stemphylium leaf blight has been considered a minor foliar disease as it has not done much damage in New York since the early 1990s.

Read More: Disease News and Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.